Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Guanosine nucleotides inhibit different syndromes of PTHrP excess caused by human cancers in vivo
Wolfgang E. Gallwitz, Theresa A. Guise, Gregory R. Mundy
Wolfgang E. Gallwitz, Theresa A. Guise, Gregory R. Mundy
View: Text | PDF
Article Development

Guanosine nucleotides inhibit different syndromes of PTHrP excess caused by human cancers in vivo

  • Text
  • PDF
Abstract

Research Article

Authors

Wolfgang E. Gallwitz, Theresa A. Guise, Gregory R. Mundy

×

Figure 8

Options: View larger image (or click on image) Download as PowerPoint
Effect of 6-thioguanine and 6-thioguanosine on osteoclast number per mil...
Effect of 6-thioguanine and 6-thioguanosine on osteoclast number per millimeter of tumor per bone. Data represent histomorphometric analysis of hindlimbs from mice with osteolytic lesions. MDA-MB-231 tumor cells were inoculated on day 0. Treatment with either 6-thioguanine or 6-thioguanosine (1.0 mg/kg/day subcutaneously) was begun on the following day. Measurements are of the number of osteoclasts per millimeter of tumor adjacent to bone (tumor–bone interface) from the midsections of tibias and femurs of mice. Values represent means ± SEM (n = 5 per group). 6-TG, 6-thioguanine; 6-TGu, 6-thioguanosine. *P < 0.05.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts